OPKO Health Enters into License Agreement with International Health Technology for Next Generation Prostate Cancer Biomarker Panel May 4, 2012
OPKO Health Announces the Start of Phase 3 Clinical Trials of Rolapitant for the Prevention of CINV Apr 12, 2012
OPKO Health and The Scripps Research Institute Announce Global License Agreement for a Novel Compound That Blocks Brain Cell Destruction in Parkinson’s Disease Mar 9, 2012
